Your browser doesn't support javascript.
loading
Neuroprotective and Antioxidant Effects of Riparin I in a Model of Depression Induced by Corticosterone in Female Mice.
Maia Oliveira, Iris Cristina; Vasconcelos Mallmann, Auriana Serra; Adelvane de Paula Rodrigues, Francisco; Teodorio Vidal, Laura Maria; Lopes Sales, Iardja Stéfane; Rodrigues, Gabriel Carvalho; Ferreira de Oliveira, Natalia; de Castro Chaves, Raquell; Cavalcanti Capibaribe, Victor Celso; Rodrigues de Carvalho, Alyne Mara; Maria de França Fonteles, Marta; Chavez Gutierrez, Stanley Juan; Barbosa-Filho, José Maria; Florenço de Sousa, Francisca Cléa.
  • Maia Oliveira IC; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Vasconcelos Mallmann AS; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Adelvane de Paula Rodrigues F; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Teodorio Vidal LM; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Lopes Sales IS; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil, iardjastefane@hotmail.com.
  • Rodrigues GC; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Ferreira de Oliveira N; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • de Castro Chaves R; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Cavalcanti Capibaribe VC; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Rodrigues de Carvalho AM; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • Maria de França Fonteles M; Department of Pharmacy, Federal University of Ceará, Fortaleza, Brazil.
  • Chavez Gutierrez SJ; Department of Pharmacy, Laboratory of Chemical Technology, Federal University of Piauí, Teresina, Brazil.
  • Barbosa-Filho JM; Department of Pharmacy, Laboratory of Pharmaceutical Technology, Federal University of Paraiba, João Pessoa, Brazil.
  • Florenço de Sousa FC; Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Neuropsychobiology ; 81(1): 28-38, 2022.
Article en En | MEDLINE | ID: mdl-33915549
BACKGROUND: Depression is a common, chronic, and often recurrent serious mood disorder. Conventional antidepressants present limitations that stimulate the search for new drugs. Antioxidant and neuroprotective substances are potential antidepressant agents. In this context, riparin I (RIP I) has presented promising results, emerging as a potential source of a new therapeutic drug. In this study, the antidepressant effect of RIP I was evaluated in an animal model of depression induced by corticosterone (CORT). The involvement of neuroprotective and antioxidant mechanisms in the generation of this effect was also assessed. METHODS: Female mice were submitted to CORT for 21 days and treated with RIP I in the last 7 days. Behavioral and neurochemical analyses were performed. RESULTS: The administration of RIP I reversed the depressive and psychotic-like behavior, as well as the cognitive impairment caused by CORT, in addition to regulating oxidative stress parameters and BDNF levels in depression-related brain areas. CONCLUSION: These findings suggest that RIP I can be a strong candidate for drugs in the treatment of depression.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticosterona / Antioxidantes Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticosterona / Antioxidantes Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article